Relmacabtagene Autoleucel as Second-Line Therapy in Adult Patients With Aggressive B-cell NHL
Status:
Not yet recruiting
Trial end date:
2027-02-01
Target enrollment:
Participant gender:
Summary
The primary objective of this study is to asess the efficacy of Relmacabtagene autoleucel as
second-line therapy in adult patients with aggressive B-cell Non-Hodgkins Lymphoma who are
ineligible for haematopoietic stem cell transplantation.